Published in Cardiovasc Diabetol on March 10, 2015
Matrix Metalloproteinase-1 and Matrix Metalloproteinase-9 in the Aqueous Humor of Diabetic Macular Edema Patients. PLoS One (2016) 0.78
Circulating Biomarkers of Diabetic Retinopathy: An Overview Based on Physiopathology. J Diabetes Res (2016) 0.77
High glucose-induced hyperosmolarity contributes to COX-2 expression and angiogenesis: implications for diabetic retinopathy. Cardiovasc Diabetol (2016) 0.76
Myricetin, a potent natural agent for treatment of diabetic skin damage by modulating TIMP/MMPs balance and oxidative stress. Oncotarget (2016) 0.75
Plasma matrix metalloproteinases are associated with incident cardiovascular disease and all-cause mortality in patients with type 1 diabetes: a 12-year follow-up study. Cardiovasc Diabetol (2017) 0.75
Mirroring the CANTOS revolution: is anti-inflammatory therapy for diabetes just around the corner? Cardiovasc Diabetol (2017) 0.75
Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem (1972) 95.79
A new equation to estimate glomerular filtration rate. Ann Intern Med (2009) 71.41
Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res (2003) 13.22
Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res (2002) 6.37
Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem (1982) 4.93
Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia (2003) 4.33
Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science (2000) 3.75
Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo. Blood (2002) 3.58
The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim Biophys Acta (2010) 3.33
Direct measurement of high-density lipoprotein cholesterol in serum with polyethylene glycol-modified enzymes and sulfated alpha-cyclodextrin. Clin Chem (1995) 3.20
Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol (2007) 3.19
Methodology for retinal photography and assessment of diabetic retinopathy: the EURODIAB IDDM complications study. Diabetologia (1995) 2.27
C-reactive protein induces matrix metalloproteinase-1 and -10 in human endothelial cells: implications for clinical and subclinical atherosclerosis. J Am Coll Cardiol (2006) 2.20
Cardiovascular disease and its risk factors in IDDM in Europe. EURODIAB IDDM Complications Study Group. Diabetes Care (1996) 2.11
High risk of cardiovascular disease in patients with type 1 diabetes in the U.K.: a cohort study using the general practice research database. Diabetes Care (2006) 1.94
Matrix metalloproteinases in early diabetic retinopathy and their role in alteration of the blood-retinal barrier. Lab Invest (2005) 1.92
Evidence of increased inflammation and microcirculatory abnormalities in patients with type 1 diabetes and their role in microvascular complications. Diabetes (2007) 1.84
Vascular risk factors and markers of endothelial function as determinants of inflammatory markers in type 1 diabetes: the EURODIAB Prospective Complications Study. Diabetes Care (2003) 1.75
Matrix metalloproteinases and their natural inhibitors in fibrovascular membranes of proliferative diabetic retinopathy. Br J Ophthalmol (2000) 1.73
TIMP-1 inhibits microvascular endothelial cell migration by MMP-dependent and MMP-independent mechanisms. Exp Cell Res (2004) 1.61
Matrix metalloproteinase-10 plays an active role in microvascular complications in type 1 diabetic patients. Diabetologia (2013) 1.43
Markers of insulin resistance are strong risk factors for retinopathy incidence in type 1 diabetes. Diabetes Care (2001) 1.38
Microalbuminuria in type 1 diabetes: rates, risk factors and glycemic threshold. Kidney Int (2001) 1.26
Plasma tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9: novel indicators of left ventricular remodelling and prognosis after acute myocardial infarction. Eur Heart J (2008) 1.26
Matrix metalloproteinase-2 dysregulation in type 1 diabetes. Diabetes Care (2007) 1.23
Matrix metalloproteinase-2 in the development of diabetic retinopathy and mitochondrial dysfunction. Lab Invest (2010) 1.18
Elevated circulating levels of matrix metalloproteinase-9 in type 1 diabetic patients with and without retinopathy. Clin Chim Acta (2006) 1.18
Early urinary and plasma biomarkers for experimental diabetic nephropathy. Clin Lab (2012) 1.15
Markers of endothelial dysfunction in the prediction of coronary artery disease in type 1 diabetes. The Pittsburgh Epidemiology of Diabetes Complications Study. J Diabetes Complications (2005) 1.09
Soluble vascular cell adhesion molecule-1 and soluble E-selectin are associated with micro- and macrovascular complications in Type 1 diabetic patients. J Diabetes Complications (2006) 1.09
Regulation of matrix metalloproteinase (matrixin) genes in blood vessels: a multi-step recruitment model for pathological remodelling. J Vasc Res (2003) 1.04
Matrix metalloproteinases and diabetic vascular complications. Angiology (2005) 1.01
Cardiovascular disease risk in young people with type 1 diabetes. J Cardiovasc Transl Res (2012) 1.01
In situ hybridization studies of matrix metalloproteinase-3, tissue inhibitor of metalloproteinase-1 and type IV collagen in diabetic nephropathy. Kidney Int (1997) 0.98
Disease and gender-specific dysregulation of NGAL and MMP-9 in type 1 diabetes mellitus. Endocrine (2010) 0.94
Genetic variation, gene-expression and circulating levels of matrix metalloproteinase-9 in patients with stable coronary artery disease. Clin Chim Acta (2011) 0.92
Matrix metalloproteinases in subjects with type 1 diabetes. BMC Clin Pathol (2009) 0.91
Metalloproteinases in diabetics and nondiabetics during acute coronary syndromes and after 3 months. Endothelium (2007) 0.83
Dysregulation of matrix metalloproteinases and their tissue inhibitors is related to abnormality of left ventricular geometry and function in streptozotocin-induced diabetic minipigs. Int J Exp Pathol (2008) 0.82
Preanalytical pitfalls of blood sampling to measure true circulating matrix metalloproteinase 9 and tissue inhibitors of matrix metalloproteinases. Clin Chim Acta (2006) 0.80
Structural arrangement of collagen fibrils in the periarterial connective tissue of the kidney: their functional relevance as a structural stabilizer against arterial pressure. Anat Sci Int (2011) 0.78
Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature (2011) 13.25
Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med (2012) 9.46
Vascular risk factors and diabetic neuropathy. N Engl J Med (2005) 7.69
Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation (2007) 3.12
Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet (2008) 2.89
Treatment and prevention of obesity--are there critical periods for intervention? Int J Epidemiol (2006) 2.81
Community-based interventions to promote blood pressure control in a developing country: a cluster randomized trial. Ann Intern Med (2009) 2.64
Meta-analysis of dose-response relationships for hydrochlorothiazide, chlorthalidone, and bendroflumethiazide on blood pressure, serum potassium, and urate. Hypertension (2012) 2.48
Cost-effectiveness of community-based strategies for blood pressure control in a low-income developing country: findings from a cluster-randomized, factorial-controlled trial. Circulation (2011) 2.44
Ethnicity, socio-economic position and gender--do they affect reported health-care seeking behaviour? Soc Sci Med (2003) 2.43
The relationship between metabolic risk factors and incident cardiovascular disease in Europeans, South Asians, and African Caribbeans: SABRE (Southall and Brent Revisited) -- a prospective population-based study. J Am Coll Cardiol (2013) 2.36
Diabetic retinopathy is associated with mortality and cardiovascular disease incidence: the EURODIAB prospective complications study. Diabetes Care (2005) 2.25
Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes--the EURODIAB Prospective Complications Study. Diabetologia (2005) 2.16
Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann Intern Med (2009) 2.14
Relationship between risk factors and mortality in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study (PCS). Diabetes Care (2008) 2.14
Prevalence of overweight and obesity and their association with hypertension and diabetes mellitus in an Indo-Asian population. CMAJ (2006) 2.13
Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. Diabetes Care (2003) 2.05
Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant (2009) 2.02
High risk of cardiovascular disease in patients with type 1 diabetes in the U.K.: a cohort study using the general practice research database. Diabetes Care (2006) 1.94
Ethnic subgroup differences in hypertension in Pakistan. J Hypertens (2003) 1.94
Use of albumin creatinine ratio and urine albumin concentration as a screening test for albuminuria in an Indo-Asian population. Nephrol Dial Transplant (2007) 1.91
beta-Catenin regulates vascular endothelial growth factor expression in colon cancer. Cancer Res (2003) 1.85
Pulse pressure is associated with age and cardiovascular disease in type 1 diabetes: the Eurodiab Prospective Complications Study. J Hypertens (2003) 1.85
Crosslinking by advanced glycation end products increases the stiffness of the collagen network in human articular cartilage: a possible mechanism through which age is a risk factor for osteoarthritis. Arthritis Rheum (2002) 1.85
Diabetes, pulse pressure and cardiovascular mortality: the Hoorn Study. J Hypertens (2002) 1.83
All-cause mortality after diabetes-related amputation in Barbados: a prospective case-control study. Diabetes Care (2008) 1.81
Measurement of Nepsilon-(carboxymethyl)lysine and Nepsilon-(carboxyethyl)lysine in human plasma protein by stable-isotope-dilution tandem mass spectrometry. Clin Chem (2004) 1.78
Vascular risk factors and markers of endothelial function as determinants of inflammatory markers in type 1 diabetes: the EURODIAB Prospective Complications Study. Diabetes Care (2003) 1.75
Abnormalities of retinal microvascular structure and risk of mortality from ischemic heart disease and stroke. Hypertension (2006) 1.74
Risk factors for cardiac autonomic neuropathy in type 1 diabetes mellitus. Diabetologia (2004) 1.73
Southall And Brent REvisited: Cohort profile of SABRE, a UK population-based comparison of cardiovascular disease and diabetes in people of European, Indian Asian and African Caribbean origins. Int J Epidemiol (2010) 1.69
Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE). J Renin Angiotensin Aldosterone Syst (2012) 1.68
ANTI-HSP60 and ANTI-HSP70 antibody levels and micro/ macrovascular complications in type 1 diabetes: the EURODIAB Study. J Intern Med (2009) 1.68
Higher levels of advanced glycation endproducts in human carotid atherosclerotic plaques are associated with a rupture-prone phenotype. Eur Heart J (2013) 1.67
Citrate anticoagulation abolishes degranulation of polymorphonuclear cells and platelets and reduces oxidative stress during haemodialysis. Nephrol Dial Transplant (2005) 1.67
Risk factors for coronary heart disease in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study. Diabetes Care (2004) 1.64
Adapted dietary inflammatory index and its association with a summary score for low-grade inflammation and markers of glucose metabolism: the Cohort study on Diabetes and Atherosclerosis Maastricht (CODAM) and the Hoorn study. Am J Clin Nutr (2013) 1.63
Humoral markers of inflammation and endothelial dysfunction in relation to adiposity and in vivo insulin action in Pima Indians. Atherosclerosis (2002) 1.60
Association between mannose-binding lectin and vascular complications in type 1 diabetes. Diabetes (2004) 1.59
Advanced glycation end products accumulate in vascular smooth muscle and modify vascular but not ventricular properties in elderly hypertensive canines. Circulation (2008) 1.55
General practitioners' approach to hypertension in urban Pakistan: disturbing trends in practice. Circulation (2005) 1.51
Ethnicity and left ventricular diastolic function in hypertension an ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) substudy. J Am Coll Cardiol (2008) 1.51
Low-grade inflammation, but not endothelial dysfunction, is associated with greater carotid stiffness in the elderly: the Hoorn Study. J Hypertens (2012) 1.50
Impact of size at birth on the microvasculature: the Avon Longitudinal Study of Parents and Children. Pediatrics (2007) 1.49
Endogenous formation of Nε-(carboxymethyl)lysine is increased in fatty livers and induces inflammatory markers in an in vitro model of hepatic steatosis. J Hepatol (2011) 1.46
Glycemic control and all-cause mortality risk in type 1 diabetes patients: the EURODIAB prospective complications study. J Clin Endocrinol Metab (2014) 1.46
Effect of low vs. high dietary sodium on blood pressure levels in a normotensive Indo-Asian population. Am J Hypertens (2008) 1.45
Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis (2009) 1.45
Lipoprotein subclasses and particle sizes and their relationship with coronary artery calcification in men and women with and without type 1 diabetes. Diabetes (2002) 1.43
Relation between blood glucose and coronary mortality over 33 years in the Whitehall Study. Diabetes Care (2006) 1.43
Effects of transdermal and oral postmenopausal hormone therapy on vascular function: a randomized, placebo-controlled study in healthy postmenopausal women. Menopause (2005) 1.42
Protein intake in relation to risk of hypertension and microalbuminuria in patients with type 1 diabetes: the EURODIAB Prospective Complications Study. J Hypertens (2013) 1.41
Microalbuminuria and coronary heart disease risk in an ethnically diverse UK population: a prospective cohort study. J Am Soc Nephrol (2005) 1.38
Impaired renal function is associated with markers of endothelial dysfunction and increased inflammatory activity. Nephrol Dial Transplant (2003) 1.37
Iron metabolism is associated with adipocyte insulin resistance and plasma adiponectin: the Cohort on Diabetes and Atherosclerosis Maastricht (CODAM) study. Diabetes Care (2012) 1.34
Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study. Diabetes Care (2011) 1.34
Explanations for the high risk of diabetes-related amputation in a Caribbean population of black african descent and potential for prevention. Diabetes Care (2004) 1.34
Differences in smoking associated DNA methylation patterns in South Asians and Europeans. Clin Epigenetics (2014) 1.33
Ethnicity and risk of diabetes-related lower extremity amputation: a population-based, case-control study of African Caribbeans and Europeans in the United kingdom. Arch Intern Med (2002) 1.32
Risk factors for progression to proliferative diabetic retinopathy in the EURODIAB Prospective Complications Study. Diabetologia (2001) 1.32
Tissue Doppler E/E' ratio is a powerful predictor of primary cardiac events in a hypertensive population: an ASCOT substudy. Eur Heart J (2009) 1.30
Large-fiber dysfunction in diabetic peripheral neuropathy is predicted by cardiovascular risk factors. Diabetes Care (2009) 1.29
Insulin resistance and truncal obesity as important determinants of the greater incidence of diabetes in Indian Asians and African Caribbeans compared with Europeans: the Southall And Brent REvisited (SABRE) cohort. Diabetes Care (2012) 1.29
Children in South Asia have higher body mass-adjusted blood pressure levels than white children in the United States: a comparative study. Circulation (2005) 1.28
Heart disease epidemic in Pakistan: women and men at equal risk. Am Heart J (2005) 1.28
Overexpression of glyoxalase-I reduces hyperglycemia-induced levels of advanced glycation end products and oxidative stress in diabetic rats. J Biol Chem (2010) 1.27
Self-rated health in Pakistan: results of a national health survey. BMC Public Health (2005) 1.27
Long-term exposure to new peritoneal dialysis solutions: Effects on the peritoneal membrane. Kidney Int (2004) 1.26
Effect of general practitioner education on adherence to antihypertensive drugs: cluster randomised controlled trial. BMJ (2007) 1.24
Diabetes mellitus worsens diastolic left ventricular dysfunction in aortic stenosis through altered myocardial structure and cardiomyocyte stiffness. Circulation (2011) 1.22
Reference intervals for common carotid intima-media thickness measured with echotracking: relation with risk factors. Eur Heart J (2012) 1.21
Endothelial dysfunction and low-grade inflammation are associated with greater arterial stiffness over a 6-year period. Hypertension (2011) 1.19
Slightly elevated B-type natriuretic peptide levels in a non-heart failure range indicate a worse left ventricular diastolic function in individuals with, as compared with individuals without, type 2 diabetes: the Hoorn Study. Eur J Heart Fail (2010) 1.19